Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Spero announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem for complicated UTIs after a prior CRL.

Likely continued upside bias versus peers on approval-related momentum, though magnitude may fade if broader market risk-off hits.

The article is a primary FDA-approval disclosure with specific prior CRL/resubmission context, which typically drives repricing; however, no revenue/launch guidance is provided.

AbbVie’s Allergan Aesthetics unit received FDA approval expanding SKINVIVE by JUVÉDERM from cheek to neck-line indication.

Moderate positive reaction potential, with follow-through depending on how investors value the incremental indication.

The approval is concrete and label-expansion is material for aesthetics, but the article lacks sales forecasts or competitive context.

Neumora halted its Phase 3 KOASTAL studies of Navacaprant after failing primary/secondary endpoints and plans ~35% layoffs.

Downside bias and higher probability of further financing/strategic actions as the pipeline is narrowed.

The article discloses both clinical failure (no statistical difference vs placebo) and cost-cutting, which together typically weigh on biotech risk appetite.

enGene announced a restructuring to cut its workforce by ~50% to extend cash runway and reduce operating expenses.

Likely continued weakness or volatility until investors gain clarity on remaining programs and funding needs.

Workforce cuts are a primary corporate action with explicit intent (runway extension), but no balance-sheet or financing details are provided.

Biogen agreed to acquire RayThera in a deal valued up to $1B, targeting immunology expansion, expected to close in Q3 2026.

Potential medium-term upside on strategic rationale, but near-term trading may reflect deal execution risk.

A disclosed, time-bound M&A agreement is high-quality news; however, the article provides limited detail on asset stage and valuation mechanics beyond total deal value.

Bayer received FDA approval for AMBELVIST (gadoquatrane), a next-gen MRI contrast agent with 60% lower gadolinium dose.

Mild-to-moderate positive bias; magnitude depends on commercial uptake expectations not provided here.

The article includes Phase 3 support and a differentiation metric (lower dose), but lacks market size, pricing, or launch timeline.

Neurocrine presented late-breaking Phase 3 extension data for VYKAT XR in Prader-Willi syndrome, showing durable improvements through two years.

Potential positive drift if investors view the data as supportive for future label/expansion; otherwise limited immediate repricing.

The article provides specific durability outcomes and ties to an already-approved product, but it’s not framed as a new FDA action.

Celldex reported positive Phase 2b data for Barzolvolimab in chronic spontaneous urticaria with angioedema, including sustained reduction through week 76 post-withdrawal.

Likely modest upside bias as investors price improved probability of success into the pipeline.

The article includes concrete efficacy durability and a stated Phase 3/BLA timeline, but no FDA decision is disclosed.